Ultimovacs: INITIUM failure constitutes a major setback - Redeye

Redeye believes that INITUM's failure to show improved efficacy of UV1 addition to double CPI therapy in malignant melanoma represents a major setback for the company. Ultimovacs has positive NIPU data and more shots on goal, meaning one should not write off UV1 entirely for now. Still, potential future business development and financing will likely become considerably more difficult. We intend to lower our estimates and valuation substantially.

Länk till analysen i sin helhet: https://www.redeye.se/research/989069/ultimovacs-initium-failure-constitutes-a-major-setback?utm_source=finwire&utm_medium=RSS